Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC
Status:
Recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics
(PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with
Standard(s) of Care (SOC) or with each other.
The first two subprotocols include the following:
Subprotocol A: RMC-6291 + SOC Subprotocol B: RMC-6236 + SOC